{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:06:22Z","timestamp":1776863182922,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006419","name":"EuroQol Research Foundation","doi-asserted-by":"publisher","award":["444-RA"],"award-info":[{"award-number":["444-RA"]}],"id":[{"id":"10.13039\/501100006419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The objective of this study was to evaluate the psychometric properties of the EQ-5D (3L and 5L) and SF-6Dv2 in a group of Chinese patients with late-on Pompe disease (PD), and compare their performance in this patient group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The data used in this study were obtained from a web-based and cross-sectional survey conducted in China. All participants completed the 3L, 5L, and SF-6Dv2. Information about their sociodemographic status and health conditions was also collected. The measurement properties were assessed by examining ceiling and floor effects, evaluating convergent validity, known-group validity, and test\u2013retest reliability (Intraclass correlation coefficient [ICC] and Gwet\u2019s AC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 117 PD patients completed the questionnaire. All dimensions of the 3L showed strong ceiling effects, ranging between 17.1 and 42.7%. All three measures showed good test\u2013retest reliability, with ICC values ranging from 0.85 to 0.87. The Gwet\u2019s AC values showed that four out of five dimensions of the 3L showed very good agreement. All hypothesized correlations between the 3L, 5L, SF-6Dv2, and items of WHODAS were supported, indicating satisfactory convergent validity. The 5L showed stronger correlations (|<jats:italic>r<\/jats:italic>|=\u20090.53\u20130.84) with WHODAS than the other two measures. The outcomes of ANOVA indicated that the 5L had higher <jats:italic>F<\/jats:italic>-statistics than the 3L and SF-6Dv2, indicating a stronger discriminant ability to differentiate most condition groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The 5L demonstrates lower ceiling and floor effects, higher discriminant ability, and better convergent validity than the SF-6Dv2 and 3L in patients with PD. In addition, the 5L may generate a larger utility gain compared to the other two instruments when conducting cost-effectiveness analysis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-024-01682-2","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T19:08:30Z","timestamp":1710270510000},"page":"1505-1515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Measurement properties of the EQ-5D-3L, EQ-5D-5L, and SF-6Dv2 in patients with late-onset Pompe disease"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-5172","authenticated-orcid":false,"given":"Richard Huan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9784-6472","authenticated-orcid":false,"given":"Dong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"1682_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10198-017-0902-x","volume":"19","author":"AP Finch","year":"2018","unstructured":"Finch, A.P., Brazier, J.E., Mukuria, C.: What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews. Eur. J. Health Econ. 19, 557 (2018)","journal-title":"Eur. J. Health Econ."},{"key":"1682_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.08.002","author":"J Tosh","year":"2012","unstructured":"Tosh, J., Brazier, J., Evans, P., et al.: A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health (2012). https:\/\/doi.org\/10.1016\/j.jval.2011.08.002","journal-title":"Value Health"},{"key":"1682_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jval.2018.12.001","volume":"22","author":"JE Brazier","year":"2019","unstructured":"Brazier, J.E., Rowen, D., Lloyd, A., et al.: Future directions in valuing benefits for estimating QALYs: is time up for the EQ-5D? Value Health 22, 62\u201368 (2019)","journal-title":"Value Health"},{"key":"1682_CR4","unstructured":"National institue for health and care excellence. reviewing our methods for health technology evaluation: consultation. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/chte-methods-consultation Accessed 20 July 2023"},{"key":"1682_CR5","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Lloyd, A., et al.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 20, 1727\u20131736 (2011)","journal-title":"Qual. Life Res."},{"key":"1682_CR6","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087","author":"R Rabin","year":"2001","unstructured":"Rabin, R., De Charro, F.: EQ-5D: a measure of health status from the EuroQol Group. Ann. Med. (2001). https:\/\/doi.org\/10.3109\/07853890109002087","journal-title":"Ann. Med."},{"key":"1682_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001325","author":"JE Brazier","year":"2020","unstructured":"Brazier, J.E., Mulhern, B.J., Bjorner, J.B., et al.: Developing a new version of the SF-6D health state classification system from the SF-36v2: SF-6Dv2. Med. Care (2020). https:\/\/doi.org\/10.1097\/MLR.0000000000001325","journal-title":"Med. Care"},{"key":"1682_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin, M., Slaap, B., Herdman, M., et al.: Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur. J. Health Econ. 21, 1245\u20131257 (2020)","journal-title":"Eur. J. Health Econ."},{"key":"1682_CR9","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","volume":"22","author":"B Janssen","year":"2013","unstructured":"Janssen, B., Pickard, S., Golicki, D., et al.: Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual. Life Res. 22, 1717\u20131727 (2013)","journal-title":"Qual. Life Res."},{"key":"1682_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-023-02096-z","author":"A Nikl","year":"2023","unstructured":"Nikl, A., Janssen, M.F., Brodszky, V., et al.: A head-to-head comparison of the EQ-5D-5L and 15D descriptive systems and index values in a general population sample. Health Qual. Life Outcomes (2023). https:\/\/doi.org\/10.1186\/s12955-023-02096-z","journal-title":"Health Qual. Life Outcomes"},{"key":"1682_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01114-6","author":"E McDool","year":"2021","unstructured":"McDool, E., Mukuria, C., Brazier, J.: correction to: a comparison of the SF-6Dv2 and SF-6D UK utility values in a mixed patient and healthy population. Pharmacoeconomics (2021). https:\/\/doi.org\/10.1007\/s40273-021-01114-6","journal-title":"Pharmacoeconomics"},{"key":"1682_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.02.002","author":"F Rencz","year":"2023","unstructured":"Rencz, F., Brodszky, V., Janssen, M.F.: A direct comparison of the measurement properties of EQ-5D-5L, PROMIS-29+2 and PROMIS global health instruments and EQ-5D-5L and PROPr utilities in a general population sample. Value Health (2023). https:\/\/doi.org\/10.1016\/j.jval.2023.02.002","journal-title":"Value Health"},{"key":"1682_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s11136-014-0902-6","volume":"24","author":"C-W Pan","year":"2015","unstructured":"Pan, C.-W., Sun, H.-P., Wang, X., et al.: The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Qual. Life Res. 24, 1767\u20131774 (2015)","journal-title":"Qual. Life Res."},{"key":"1682_CR14","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s11136-014-0670-3","volume":"23","author":"YX Jia","year":"2014","unstructured":"Jia, Y.X., Cui, F.Q., Li, L., et al.: Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual. Life Res. 23, 2355\u20132363 (2014)","journal-title":"Qual. Life Res."},{"key":"1682_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s11136-014-0833-2","volume":"24","author":"TA Kanters","year":"2015","unstructured":"Kanters, T.A., Redekop, W.K., Kruijshaar, M.E., et al.: Comparison of EQ-5D and SF-6D utilities in Pompe disease. Qual. Life Res. 24, 837\u2013844 (2015)","journal-title":"Qual. Life Res."},{"key":"1682_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-02003-y","author":"S Xie","year":"2022","unstructured":"Xie, S., Wang, D., Wu, J., et al.: Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey. Health Qual. Life Outcomes (2022). https:\/\/doi.org\/10.1186\/s12955-022-02003-y","journal-title":"Health Qual. Life Outcomes"},{"key":"1682_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10742-020-00215-7","author":"A Nahvijou","year":"2020","unstructured":"Nahvijou, A., Safari, H., Ameri, H.: Comparing the performance of the EQ-5D-5L with two versions of the SF-6Dv2 in patients with breast cancer. Health Serv. Outcomes Res. Methodol. (2020). https:\/\/doi.org\/10.1007\/s10742-020-00215-7","journal-title":"Health Serv. Outcomes Res. Methodol."},{"key":"1682_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","volume":"39","author":"D G\u00fcng\u00f6r","year":"2016","unstructured":"G\u00fcng\u00f6r, D., Kruijshaar, M., Plug, I., et al.: Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J. Inherit. Metab. Dis. 39, 253\u2013260 (2016)","journal-title":"J. Inherit. Metab. Dis."},{"key":"1682_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s41687-021-00336-8","volume":"5","author":"WR Lenderking","year":"2021","unstructured":"Lenderking, W.R., Anatchkova, M., Pokrzywinski, R., et al.: Measuring health-related quality of life in patients with rare disease. J. Patient Rep. Outcomes 5, 61 (2021)","journal-title":"J. Patient Rep. Outcomes"},{"key":"1682_CR20","unstructured":"Abbas, A., Vella, J., Serracino-Inglott, A.: Access to orphan drugs and quality of life in rare disease. JACCP J. Am. Coll. Clin. Pharm. 1 (2018)"},{"key":"1682_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","volume":"63","author":"MLC Hagemans","year":"2004","unstructured":"Hagemans, M.L.C., Janssens, A.C.J.W., Winkel, L.P.F., et al.: Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 63, 1688\u20131692 (2004)","journal-title":"Neurology"},{"key":"1682_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clineuro.2010.09.016","volume":"113","author":"S Vielhaber","year":"2010","unstructured":"Vielhaber, S., Brejova, A., Debska-Vielhaber, G., et al.: 24-Months results in two adults with Pompe disease on enzyme replacement therapy. Clin. Neurol. Neurosurg. 113, 350\u2013357 (2010)","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1682_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01836-y","author":"S Chen","year":"2021","unstructured":"Chen, S., Wang, J., Zhu, J., et al.: Quality of life and its contributors among adults with late-onset pompe disease in China. Orphanet J. Rare Dis. (2021). https:\/\/doi.org\/10.1186\/s13023-021-01836-y","journal-title":"Orphanet J. Rare Dis."},{"key":"1682_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1138996","author":"J Liu","year":"2023","unstructured":"Liu, J., Yu, Y., Zhong, M., et al.: Long way to go: progress of orphan drug accessibility in China from 2017 to 2022. Front. Pharmacol. (2023). https:\/\/doi.org\/10.3389\/fphar.2023.1138996","journal-title":"Front. Pharmacol."},{"key":"1682_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6","author":"R Brooks","year":"1996","unstructured":"Brooks, R., De Charro, F.: EuroQol: the current state of play. Health Policy (NY) (1996). https:\/\/doi.org\/10.1016\/0168-8510(96)00822-6","journal-title":"Health Policy (NY)"},{"key":"1682_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jval.2014.05.007","volume":"17","author":"GG Liu","year":"2014","unstructured":"Liu, G.G., Wu, H., Li, M., et al.: Chinese time trade-off values for EQ-5D health states. Value Health 17, 597\u2013604 (2014)","journal-title":"Value Health"},{"key":"1682_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo, N., Liu, G., Li, M., et al.: Estimating an EQ-5D-5L value set for China. Value Health 20, 662\u2013669 (2017)","journal-title":"Value Health"},{"key":"1682_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00997-1","author":"J Wu","year":"2021","unstructured":"Wu, J., Xie, S., He, X., et al.: Valuation of SF-6Dv2 Health states in China using time trade-off and discrete-choice experiment with a duration dimension. Pharmacoeconomics (2021). https:\/\/doi.org\/10.1007\/s40273-020-00997-1. (Published online first)","journal-title":"Pharmacoeconomics"},{"key":"1682_CR29","unstructured":"\u00dcst\u00fcn, TB.: Measuring Health and Disability: Manual for WHO Disability Assessment Schedule WHODAS 2.0. World Health Organization (2010)"},{"key":"1682_CR30","unstructured":"Dancey, C., Reidy, J.: Statistics without maths for psychology (2011)"},{"key":"1682_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-61","author":"N Wongpakaran","year":"2013","unstructured":"Wongpakaran, N., Wongpakaran, T., Wedding, D., et al.: A comparison of Cohen\u2019s Kappa and Gwet\u2019s AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples. BMC Med. Res. Methodol. (2013). https:\/\/doi.org\/10.1186\/1471-2288-13-61","journal-title":"BMC Med. Res. Methodol."},{"key":"1682_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis, J.R., Koch, G.G.: The measurement of observer agreement for categorical data. Biometrics 33, 159 (1977)","journal-title":"Biometrics"},{"key":"1682_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee, C.B., Bot, S.D.M., de Boer, M.R., et al.: Quality criteria were proposed for measurement properties of health status questionnaires. J. Clin. Epidemiol. 60, 34\u201342 (2007)","journal-title":"J. Clin. Epidemiol."},{"key":"1682_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-023-01574-x","author":"RH Xu","year":"2023","unstructured":"Xu, R.H., Dai, Y., Ng, S.S.M., et al.: Assessing validity of the EQ-5D-5L proxy in children and adolescents with Duchenne muscular dystrophy or spinal muscular atrophy. Eur. J. Health Econ. (2023). https:\/\/doi.org\/10.1007\/s10198-023-01574-x. (Published online first)","journal-title":"Eur. J. Health Econ."},{"key":"1682_CR35","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10198-021-01273-5","volume":"22","author":"RH Xu","year":"2021","unstructured":"Xu, R.H., Dong, D., Luo, N., et al.: Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia. Eur. J. Health Econ. 22, 547\u2013557 (2021)","journal-title":"Eur. J. Health Econ."},{"key":"1682_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01551-w","author":"RH Xu","year":"2022","unstructured":"Xu, R.H., Lu, M., Zhang, S., et al.: EQ-5D and SF-6D health utility scores in patients with spinal and bulbar muscular atrophy. Eur. J. Health Econ. (2022). https:\/\/doi.org\/10.1007\/s10198-022-01551-w. (Published online first)","journal-title":"Eur. J. Health Econ."},{"key":"1682_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00466-z","author":"X Zeng","year":"2021","unstructured":"Zeng, X., Sui, M., Liu, B., et al.: Measurement properties of the EQ-5D-5L and EQ-5D-3L in six commonly diagnosed cancers. Patient (2021). https:\/\/doi.org\/10.1007\/s40271-020-00466-z","journal-title":"Patient"},{"key":"1682_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290606","author":"O Marten","year":"2023","unstructured":"Marten, O., Greiner, W.: Exploring differences and similarities of EQ- 5D-3L, EQ-5D-5L and WHOQOL-OLD in recipients of aged care services in Germany. PLoS ONE (2023). https:\/\/doi.org\/10.1371\/journal.pone.0290606","journal-title":"PLoS ONE"},{"key":"1682_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02732-x","author":"A Bat\u00f3","year":"2021","unstructured":"Bat\u00f3, A., Brodszky, V., Gergely, L.H., et al.: The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Qual. Life Res. (2021). https:\/\/doi.org\/10.1007\/s11136-020-02732-x","journal-title":"Qual. Life Res."},{"key":"1682_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-022-01460-y","author":"K Koszor\u00fa","year":"2023","unstructured":"Koszor\u00fa, K., Hajdu, K., Brodszky, V., et al.: Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis. Eur. J. Health Econ. (2023). https:\/\/doi.org\/10.1007\/s10198-022-01460-y","journal-title":"Eur. J. Health Econ."},{"key":"1682_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.10.006","author":"A Lucia","year":"2021","unstructured":"Lucia, A., Martinuzzi, A., Nogales-Gadea, G., et al.: Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul. Disord. (2021). https:\/\/doi.org\/10.1016\/j.nmd.2021.10.006","journal-title":"Neuromuscul. Disord."},{"key":"1682_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0444-9","author":"T Morel","year":"2016","unstructured":"Morel, T., Aym\u00e9, S., Cassiman, D., et al.: Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers. Orphanet J. Rare Dis. (2016). https:\/\/doi.org\/10.1186\/s13023-016-0444-9","journal-title":"Orphanet J. Rare Dis."},{"key":"1682_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-035722","author":"TG Poder","year":"2020","unstructured":"Poder, T.G., Wang, L., Carrier, N.: EQ-5D-5L and SF-6Dv2 utility scores in people living with chronic low back pain: a survey from Quebec. BMJ Open (2020). https:\/\/doi.org\/10.1136\/bmjopen-2019-035722","journal-title":"BMJ Open"},{"key":"1682_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12955-014-0203-3","volume":"13","author":"J Pattanaphesaj","year":"2015","unstructured":"Pattanaphesaj, J., Thavorncharoensap, M.: Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health Qual. Life Outcomes 13, 14 (2015)","journal-title":"Health Qual. Life Outcomes"},{"key":"1682_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-0018-1","author":"SH Kim","year":"2012","unstructured":"Kim, S.H., Kim, H.J., Lee, S.-i, et al.: Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Qual. Life Res. (2012). https:\/\/doi.org\/10.1007\/s11136-011-0018-1","journal-title":"Qual. Life Res."},{"key":"1682_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-3211-7","author":"K Stavem","year":"2005","unstructured":"Stavem, K., Fr\u00f8land, S.S., Hellum, K.B.: Comparison of preference\u2013based utilities of the 15D, EQ-5D and SF-6D in patients with HIV\/AIDS. Qual. Life Res. (2005). https:\/\/doi.org\/10.1007\/s11136-004-3211-7","journal-title":"Qual. Life Res."},{"key":"1682_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.06.012","author":"F Rencz","year":"2022","unstructured":"Rencz, F., Janssen, M.F.: Analyzing the pain\/discomfort and anxiety\/depression composite domains and the meaning of discomfort in the EQ-5D: a mixed-methods study. Value Health (2022). https:\/\/doi.org\/10.1016\/j.jval.2022.06.012","journal-title":"Value Health"},{"key":"1682_CR48","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12465016","author":"DK Whynes","year":"2013","unstructured":"Whynes, D.K., Sprigg, N., Selby, J., et al.: Testing for differential item functioning within the EQ-5D. Med. Decis. Mak. (2013). https:\/\/doi.org\/10.1177\/0272989X12465016","journal-title":"Med. Decis. Mak."},{"key":"1682_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.06.005","author":"AB Smith","year":"2016","unstructured":"Smith, A.B., Cocks, K., Parry, D., et al.: A differential item functioning analysis of the EQ-5D in cancer. Value Health (2016). https:\/\/doi.org\/10.1016\/j.jval.2016.06.005","journal-title":"Value Health"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-024-01682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-024-01682-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-024-01682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T16:02:34Z","timestamp":1729958554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-024-01682-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1682"],"URL":"https:\/\/doi.org\/10.1007\/s10198-024-01682-2","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"10 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study proposal and informed consent were approved by the Institutional Review Board of the Hong Kong Polytechnic University (Ref ID: HSEARS20220829001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}